Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
This study will test whether the combination of radiation and Dostarlimab is an effective treatment for women with MMR-D/MSI-H endometrial cancer who have recently undergone surgery.
Endometrial Cancer
RADIATION: Intensity modulated radiation therapy (IMRT)|DRUG: Dostarlimab|RADIATION: Hypofractionated IMRT
Incidence of dose limiting toxicities (DLTs) (Safety Run-in only), 6-18 patients will be enrolled during a safety run-in period to assess toxicities. (NCI Common Terminology Criteria for Adverse Events version 5.0), up to 8 weeks|Progression-free (PFS), PFS will be defined as the number of days from the date of the first dose of drug to the date of an event of disease progression/recurrence, according to RECIST criteria version 1.1, 2 years
This study will test whether the combination of radiation and Dostarlimab is an effective treatment for women with MMR-D/MSI-H endometrial cancer who have recently undergone surgery.